XBiotech Inc. (NASDAQ:XBIT - Get Free Report) crossed below its fifty day moving average during trading on Tuesday . The stock has a fifty day moving average of $2.88 and traded as low as $2.80. XBiotech shares last traded at $3.08, with a volume of 44,965 shares trading hands.
XBiotech Stock Performance
The company's 50-day moving average price is $2.89 and its 200 day moving average price is $3.13. The stock has a market cap of $87.50 million, a PE ratio of -2.22 and a beta of 0.98.
XBiotech (NASDAQ:XBIT - Get Free Report) last released its earnings results on Wednesday, May 14th. The biopharmaceutical company reported ($0.36) earnings per share (EPS) for the quarter.
Institutional Inflows and Outflows
Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Hsbc Holdings PLC purchased a new position in shares of XBiotech in the first quarter valued at $52,000. Nuveen LLC purchased a new position in shares of XBiotech in the first quarter valued at $81,000. Charles Schwab Investment Management Inc. grew its holdings in shares of XBiotech by 15.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 67,355 shares of the biopharmaceutical company's stock valued at $218,000 after purchasing an additional 8,918 shares in the last quarter. Deutsche Bank AG purchased a new position in shares of XBiotech in the fourth quarter valued at $120,000. Finally, Bank of America Corp DE grew its holdings in shares of XBiotech by 42.0% in the fourth quarter. Bank of America Corp DE now owns 19,888 shares of the biopharmaceutical company's stock valued at $79,000 after purchasing an additional 5,887 shares in the last quarter. 55.70% of the stock is currently owned by institutional investors.
XBiotech Company Profile
(
Get Free Report)
XBiotech Inc, a biopharmaceutical company, discovers, develops, and commercializes True Human monoclonal antibodies for treating various diseases. The company focuses on developing a pipeline of product candidates targeting both inflammatory and infectious diseases. It is also developing interleukin-1 alpha therapies to treat variety of medical conditions, such as cancer, stroke, heart attack, or arthritis; and mediates tissue breakdown, angiogenesis, the formation of blood clots, malaise, muscle wasting, and inflammation.
Recommended Stories
Before you consider XBiotech, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and XBiotech wasn't on the list.
While XBiotech currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
